Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erin Yu

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
American Journal of Obstetrics and Gynecology|August 16, 2024
Distinct obstetrical characteristics and maternal mortality in patients with HELLP syndrome vs severe preeclampsiaJulia N Kuhn, Genevieve R Mazza, Shinya Matsuzaki, et al.
American Journal of Obstetrics and Gynecology|June 22, 2024
Temporal trends of obstetric hemorrhage and product-specific blood transfusion at time of deliveryRauvynne N Sangara, Kazuhide Matsushima, Shinya Matsuzaki, et al.
Gynecologic Oncology Reports|August 7, 2024
Temporal trends of adolescents and young adults (AYA) with gynecologic malignancy in the United StatesChristian Pino, Matthew W Lee, Zachary S Anderson, et al.
Hematological Oncology|August 31, 2022
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myelomaNing Xu, Erin Yu, Nicole Ng, et al.
British Journal of Haematology|December 20, 2020
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myelomaHaiming Chen, Mingjie Li, Nicole Ng, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
American Journal of Obstetrics and Gynecology|August 16, 2024
Distinct obstetrical characteristics and maternal mortality in patients with HELLP syndrome vs severe preeclampsiaJulia N Kuhn, Genevieve R Mazza, Shinya Matsuzaki, et al.
American Journal of Obstetrics and Gynecology|June 22, 2024
Temporal trends of obstetric hemorrhage and product-specific blood transfusion at time of deliveryRauvynne N Sangara, Kazuhide Matsushima, Shinya Matsuzaki, et al.
Gynecologic Oncology Reports|August 7, 2024
Temporal trends of adolescents and young adults (AYA) with gynecologic malignancy in the United StatesChristian Pino, Matthew W Lee, Zachary S Anderson, et al.
Hematological Oncology|August 31, 2022
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myelomaNing Xu, Erin Yu, Nicole Ng, et al.
British Journal of Haematology|December 20, 2020
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myelomaHaiming Chen, Mingjie Li, Nicole Ng, et al.
Pageof 2